Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Jaguar Animal Health ( (JAGX) ) is now available.
On May 13 and 14, 2025, Jaguar Health, Inc. executed several stock exchange agreements to manage its financial obligations. The company issued common and preferred stock to reduce outstanding royalty interests and replace existing preferred stock, impacting its financial structure and shareholder equity. These transactions are part of Jaguar’s broader strategy to optimize its capital structure and potentially improve its market positioning. Additionally, Jaguar reported a decrease in first-quarter 2025 revenue compared to the previous year and quarter, with a notable increase in sales and marketing expenses due to expanded market access activities.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s stock score is low due to substantial financial difficulties, characterized by high leverage, negative profitability, and bearish technical indicators. While there is some optimism from earnings calls and corporate events, persistent financial instability and clinical trial challenges weigh heavily on the stock’s potential.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of gastrointestinal products. Its primary products include Mytesi, Gelclair, and Canalevia-CA1, with a market focus on both prescription and non-prescription products.
Average Trading Volume: 111,873
Technical Sentiment Signal: Sell
Current Market Cap: $4.45M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.